ET
Therapeutic Areas
Elevara Medicines Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ELV001 | Rheumatoid Arthritis (inadequate response to MTX and TNF inhibitors) | Phase 2b |
Leadership Team at Elevara Medicines
PD
Professor Dominique Baeten, M.D., Ph.D.
CMO
GB
Geoff Brooks
Head of Clinical Operations
KW
Kirsty Wydenbach, BSc MBBS MSc FRCA FFPM
Head of Regulatory
SH
Simon Hutchings, Ph.D.
Head of Clinical Pharmacology
MJ
Margaret Jones, Ph.D.
Head of Biometrics